title: Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours?
authors.forename: Roger
authors.initials: R
authors.lastname: Henriksson
authors.forename: Per
authors.initials: P
authors.lastname: Bergström
authors.forename: Mikael
authors.initials: M
authors.lastname: Johansson
authors.forename: Maria
authors.initials: M
authors.lastname: Sandström
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D005260:Female; D005909:Glioblastoma / Q000098:blood supply / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab